|

Clinical Study of HRS-2129 for Acute Gouty Arthritis

RECRUITINGPhase 2Sponsored by Shandong Suncadia Medicine Co., Ltd.
Actively Recruiting
PhasePhase 2
SponsorShandong Suncadia Medicine Co., Ltd.
Started2026-08-19
Est. completion2026-10
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07706777

Summary

The study is being conducted to evaluate the safety, and efficacy of HRS-2129 for acute gouty arthritis. To explore the reasonable dosage of HRS-2129 for acute gouty arthritis.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Able and willing to provide a written informed consent
2. Subjects requiring Acute gouty arthritis
3. Target joint VAS pain score ≥ 50 mm (screening)

Exclusion Criteria:

1. Subjects with a history of severe allergies
2. Subjects with nervous system disease
3. Subjects with a history of mental illness
4. Subjects with abnormal liver and renal function
5. Subjects with poorly controlled hypertensive
6. QTc：\>450ms（male），\>470ms（female）
7. History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)
8. The investigators determined that other conditions were inappropriate for participation in this clinical trial

Conditions2

Acute Gouty ArthritisArthritis

Interventions1

HRS-2129 Tablet

Browse More Trials

Arthritis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.